Posted 8th September 2023 by Ellie Egginton
Enabled by clonal-level microbiome profiling engraftment analysis, metabolomics and multi-omics analysis
The Microbiome & Probiotics R&D and Business Collaboration Forum recently hosted Marianne Koliana, VP of Business Development at Clinical Microbiomics. In the presentation she delved into crucial aspects of clinical trials, including regulatory compliance, engraftment analysis, and the pivotal role of multi-omics approaches, offering a comprehensive understanding of the evolving field.
Unravelling the Complexity of NAFLD: Insights from Professor Chris Byrne’s Presentation at the Global NASH Congress
Posted 8th June 2023 by Nicholas Noakes
The 6th Global NASH Congress in London witnessed an enlightening presentation by Professor Chris Byrne, a distinguished metabolic physician and endocrinologist. His comprehensive exploration of non-alcoholic fatty liver disease (NAFLD) unveiled its intricate nature as a multisystem disorder. This blog post aims to delve deeper into the key insights shared by Professor Byrne, elaborating on the relationship between NAFLD and type 2 diabetes, the significance of diagnosing NAFLD in patients living with diabetes, the potential benefits of PPAR gamma agonists, and the amplified risk of extrahepatic complications in NAFLD when people have type 2 diabetes.
Posted 11th May 2023 by Nicholas Noakes
Scott Harris, the Chief Medical Officer of Altimmune, gave a keynote address at the 6th Global NASH Congress where he discussed the development of drugs for both obesity and the treatment of NASH. He began by describing the statistics on obesity in the US and the lack of effective and safe therapies for the treatment of obesity in the past. He then highlighted the recent breakthroughs in incretin-based therapies, such as GLP-1, GLP-1/GIP, and GLP-1/glucagon dual agonists, which have shown promising results in clinical trials.
Posted 6th October 2022 by Nicholas Noakes
Digital health solutions in general have a poor track record of being sustained once they are implemented, often resulting in abandonment of the technology. Current digital pathology and artificial intelligence (AI) deployment strategies are generally too IT-focused – the technology being the focus, rather than the people and environment into which they are being deployed. Furthermore, a focus on technology alone will also hamper the effective integration of AI tools into the diagnostic workflow.
Posted 11th March 2022 by Nicholas Noakes
Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.Prof Alexi Baidoshvili
Posted 10th January 2022 by Nicholas Noakes
It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.
Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology
Posted 30th September 2021 by Nicholas Noakes
“What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.“
Dr Hamid Tizhoosh